A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics-Reference-Cited by-同舟云学术

A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics

Published:2013-06-06 Issue:6 Volume:19 Page:853-860
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Shirahata A.¹,Fukutake K.²,Takamatsu J.³,Shima M.⁴,Hanabusa H.⁵,Mugishima H.⁶,Amano K.²,Takedani H.⁷,Tamashima S.⁸,Matsushita T.⁹,Tawa A.¹⁰,Tanaka I.⁴,Higasa S.¹¹,Kosaka Y.¹²,Fujii T.¹³,Sakai M.¹⁴,Migita M.¹⁵,Kawakami K.¹⁶,Ohashi Y.¹⁷,Saito H.¹⁸

Affiliation:

1. Kitakyushu Yahata Higashi Hospital; Kitakyushu Fukuoka

2. Department of Laboratory Medicine; Tokyo Medical University; Tokyo

3. Japanese Red Cross Aichi Blood Center; Seto Aichi

4. Department of Paediatrics; Nara Medical University; Kashihara Nara

5. Department of Haematology; Ogikubo Hospital; Tokyo

6. Department of Paediatrics; Nihon University Itabashi Hospital; Tokyo

7. Department of Joint Surgery; Research Hospital of the Institute of Medical Science; The University of Tokyo; Tokyo

8. Department of Haematology and Oncology; Seirei Hamamatsu General Hospital; Hamamatsu Shizuoka

9. Department of Transfusion Medicine; Nagoya University Hospital; Nagoya

10. Department of Paediatrics; National Hospital Organization Osaka National Hospital; Osaka

11. Division of Haematology; Department of Internal Medicine; Hyogo College of Medicine; Nishinomiya Hyogo

12. Department of Haematology and Oncology; Kobe Children's Hospital; Kobe

13. Division of the Blood Transfusion; Hiroshima University Hospital; Hiroshima

14. Department of Paediatrics; University of Occupational and Environmental Health; Kitakyushu Fukuoka

15. Department of Paediatrics; Kumamoto Red Cross Hospital; Kumamoto

16. Department of Paediatrics; Kagoshima City Hospital; Kagoshima

17. Department of Biostatistics; School of Public Health; The University of Tokyo; Tokyo

18. National Hospital Organization Nagoya Medical Center; Nagoya Japan

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.12205/fullpdf

Reference16 articles.

1. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience;Schneiderman;Haemophilia,2007

2. Sequential therapy with activated prothrombin complex concentrate (FEIBA) and recombinant factor VIIa in a patient with severe haemophilia A, inhibitor presence and refractory bleeding;Economou;Haemophilia,2008

3. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma;Livnat;Haemophilia,2008

4. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with hemophilia and inhibitors;Gringeri;Haemophilia,2011

5. Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects;Møss;J Thromb Haemost,2009

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro;Thrombosis Research;2024-05

2. Activated protein C resistance in the copresence of emicizumab and activated prothrombin complex concentrates;Research and Practice in Thrombosis and Haemostasis;2024-05

3. Additional Factor X Enhances Emicizumab-Driven Coagulation Function in Patients with Hemophilia A and Hemophilia A Mice;Thrombosis and Haemostasis;2024-04-27

4. Cerebral infarction in a patient with inhibitor-positive hemophilia B treated with plasma-derived factor VIIa and factor X mixture;Annals of Hematology;2024-04-13

5. Coagulation potentials of plasma‐derived factors VIIa and X mixture (Byclot^®) evaluated by global coagulation assay in patients with acquired haemophilia A;Haemophilia;2023-11-29